NuvOx Pharma Receives $2M SBIR Grant for Pancreatic Cancer Diagnostic Development

Evan Unger, MD, President and CEO of NuvOx Pharma, announced that NuvOx has received a $2M Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute to fund the development of a new strategy to detect pancreatic cancer.

The grant, 2R44CA203090-02, entitled “Thy-1 targeted microbubbles for early detection of pancreatic cancer,” is a joint project between NuvOx Pharma and the Department of Radiology at Stanford University.

 

NuvOx Pharma Receives $2M SBIR Grant for Pancreatic Cancer Diagnostic Development